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Giant cell tumor (GCT) of bone has occupied a central 
stage in musculoskeletal tumor practice because of its 
relatively common incidence, striking features of giant 
cell formation, severe destruction of bone (osteolysis), 
diverse but controversial topical adjuvant therapeutic op-
tions, and preponderance for local recurrences. GCT has 
oft  en been referred to as osteoclastoma due to its unusu-
ally high population of multi-nucleated giant cells.
1,2) Th  e 
terms GCT and osteoclastoma have given the impression 
of giant cells as being the major neoplastic component 
of the lesion. Many new pathophysiologic concepts have 
emerged since the discovery of a new paradigm of osteo-
Owing to striking features of numerous multinucleated cells and bone destruction, giant cell tumor (GCT) of bone, often called 
as osteoclastoma, has drawn major attractions from orthopaedic surgeons, pathologists, and radiologists. The name GCT or os-
teoclastoma gives a false impression of a tumor comprising of proliferating osteoclasts or osteoclast precursors. The underlying 
mechanisms for excessive osteoclastogenesis are intriguing and GCT has served as an exciting disease model representing a par-
adigm of osteoclastogenesis for bone biologists. The modern interpretation of GCT is predominantly osteoclastogenic stromal cell 
tumors of mesenchymal origin. A diverse array of inﬂ  ammatory cytokines and chemokines disrupts osteoblastic differentiation and 
promotes the formation of excessive multi-nucleated osteoclastic cells. Pro-osteoclastogenic cytokines such as receptor activator 
of nuclear factor kappa-B ligand (RANKL), interleukin (IL)-6, and tumor necrosis factor (TNF) as well as monocyte-recruiting chemo-
kines such as stromal cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1 participate in unfavorable os-
teoclastogenesis and bone destruction. This model represents a self-sufﬁ  cient osteoclastogenic paracrine loop in a localized area. 
Consistent with this paradigm, a recombinant RANK-Fc protein and bisphosphonates are currently being tried for GCT treatment in 
addition to surgical excision and conventional topical adjuvant therapies.
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clastogenesis in 1997; it is time to revisit the pathophysiol-
ogy of GCT to develop new mechanism-based treatments. 
Th   is article highlights a molecular pathophysiologic aspect 
of GCT that is characterized by proliferation of mesenchy-
mal stromal osteoprogenitor cells that effectively initiate 
and maintain predominant osteoclastogenesis instead of 
differentiating into osteoblasts and osteocytes. Based on 
the modern interpretation of pathophysiology, GCT is a 
predominantly osteoclastogenic stromal tumor (POST) of 
bone.
HISTORICAL PERSPECTIVE
The neoplasm known as the GCT has had multiple clas-
sifi  cations as researchers and clinicians refi  ne the under-
standing of its presentation and pathophysiology.
In 1983, McCarthy
3) wrote an elegant review article 
tracing the history of GCT starting from Boyer’s clas-
sification in 1805 of osteosarcoma and “spina ventosa”, 
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hemorrhagic cystic dilation of the bone, as the two main 
forms of bone tumor. From 1818 to the early 1950’s, most 
of the literature on GCT illuminated clinical, radiological, 
and morphological aspects as well as its histopathology. 
In what would come to be known as a giant-cell tumor, 
Astley Cooper described an expansive lesion of the fi  bular 
head through the fi  rst gross pathological drawings of GCT. 
He named the lesion “fungus medullary exostosis” and 
until the advent of the clinical use of microscopes in 1845, 
this categorization of bone tumors prevailed.
Par H. Lebert described the first microscopic ob-
servations of multinucleated giant cells and fusiform cells 
as ‘tumeur fiblastique’ in 1845. About a decade later, Sir 
James Paget provided the fi  rst description of the tumor in 
English literature in 1854. He described myeloid tumors 
of bone containing giant cells and showed illustrations of 
spindle cells and multi-nucleated giant cells based on gross 
and microscopic examination. As X-ray came into wide-
spread use around the early 1900’s, it provided a valuable 
aid to managing and diagnosing the tumor. Bloodgood,
4) 
a surgeon at Johns Hopkins University, was credited with 
coining the term “giant-cell tumor” in his publication on 
radiographic features, conservative treatment, and use of 
bone grafts. While Bloodgood focused on mainly radio-
graphic features to examine GCTs, Jaff  e and Lichtenstein
5) 
described the clinical-radiographic-histologic identity of 
GCT in 1940. Prior to Jaffe’s radiographic description of 
GCT, the term osteoclast sarcoma was proposed in the 
1920s to denote the most differentiated member of the 
GCT cellular composition. As studies were shown to sup-
port the assertion that the lesion is benign,
6) the term sar-
coma was dropped to yield the name osteoclastoma.
In an eff  ort to reduce the risk of recurrence, many 
local adjuvant therapies such as liquid nitrogen or phenol 
were proposed between the 1950’s and 1970’s.
7,8) Between 
the early 1980’s and late 1990’s, advances in understanding 
pathologic cellular biology provided additional insights 
into GCT pathophysiology. Since the discovery of key 
signaling molecules governing the osteoclast formation 
in 1997, recent studies have highlighted the interactions 
Table 1. Pathophysiology: Cytokines and Chemokines Associated with Giant-Cell Tumor
Localization Activity
Cytokine IL-1β Multinucleated giant cells Upregulates expression of MMP-9, IL-13. Correlates with vascular invasion 
and lung metastasis.
TNF-α GCT stromal cells Promote osteoclastogenesis
M-CSF GCT stromal cells Required for osteoclast fusion
ODF/RANKL/TRANCE GCT stromal cells ODF, responsible for programming osteoclast differentiation. Work with 
cofactor M-CSF.
IL-6 GCT stromal cells Activated by c-Jun overexpression. Osteoclastogenic cytokine
IL-11, IL-17, IL-34 GCT stromal cells Osteoclastogenic cytokines
RANK Monocytes Receptor for RANKL
Chemokine MCP-1 Supernatant of GCT cultures Secreted protein of neoplastic stromal cells to recruit monocytes and giant 
cells into tumor tissues as reactive tumor components. Involvement in 
CD68+ macrophage-like cell migration
IL-8 Stromal cells Possible chemoattractant involved in recruiting monocytes and giant cells.
TGF-β1 Localized in stromal cells of GCT cultures.
Cognate TGF-β receptor is found on the 
cytoplasmic membrane of giant cells. 
Provides evidence that neoplastic stromal cells are capable of inducing 
osteoclastic fusion.
SDF-1 Stromal cells Secreted protein of neoplastic stromal cells involved in recruiting 
monocytes, macrophages and hematopoietic stem cells for 
osteoclastogenesis
Enzymes MMP-2, -3, -9 Tumor giant cells Possibly responsible for the aggressive locally osteolytic nature of GCTs
MMP-13 Stromal cells Bone matrix resorption
IL: interleukin, MMP: matrix metalloproteinase, TNF: tumor necrosis factor, GCT: giant cell tumor, M-CSF: macrophage colony-stimulating factor, ODF: osteoclast 
differentiation factor, RANKL: receptor activator of nuclear factor kappa-B ligand, TRANCE: tumor necrosis factor-related activation-induced cytokine, RANK: 
receptor activator of nuclear factor kappa, MCP: monocyte chemoattractant protein, TGF-β: transforming growth factor-beta, SDF: stromal cell-derived factor.109
Kim et al. Modern Interpretation of Giant Cell Tumor of Bone
Clinics in Orthopedic Surgery • Vol. 4, No. 2, 2012 • www.ecios.org
between osteoprogenitor cells and monocytes/macro-
phages. The name ‘giant cell tumor’ gives an unintended 
impression that the giant cells are the major neoplastic 
components of the tumor. Based on current cellular and 
molecular evidence, GCT stromal cells are the major neo-
plastic or disease components. Resorptive giant cells are 
the byproducts of interactions between GCT stromal cells 
and recruited monocytes which subsequently fuse to form 
tumor osteoclasts.
9)
PATHOLOGY AND PATHOPHYSIOLOGY
GCTs have been well studied in radiologic and histologic 
arenas; but the pathogenicity remains elusive. According 
to Dahlin’s bone tumors, GCT is a distinctive neoplasm 
of undifferentiated cells. The multinucleated giant cells 
apparently result from fusion of the proliferating mononu-
clear cells, and although they are a constant and prominent 
part of these tumors, “Th   e giant cells are probably of less 
signifi  cance than the mononuclear cells. Th   e basic prolif-
erating cell has a round-to-oval or even spindle-shaped 
nucleus in the field that is a diagnostic of true GCT.”
10) 
More recent descriptions further distinguish mononuclear 
cells into monocytes and mesenchymal stromal cells.
9,11) 
Cellular markers for monocytes such as CD14 are positive 
in mononuclear cells around the blood vessels.
9,12,13) Multi-
nucleated giant cells are positively stained with CD45, 
which indicates monocyte/macrophage origin. There are 
also numerous cells which are stained for receptor activa-
tor of nuclear factor kappa-B ligand (RANKL) and stromal 
cell-derived factor (SDF)-1.
9)
Th   e GCT stromal cells are now widely understood 
to be the major neoplastic and proliferative component of 
GCTs.
2,14) This supposition is supported by the observa-
tion that only stromal cells remain and flourish in GCT 
tissue subcultures. Furthermore, GCT stromal cells oft  en 
make osteoids, suggesting their potential to differentiate 
into osteoblastic cells. GCT stromal cells also exhibit many 
chemotactic factors which are invaluable in recruiting 
monocytic cells and the resulting fusion into resorptive gi-
ant-cells. Stromal cells in GCT secrete various chemokines 
including monocyte chemoattractant protein (MCP)-1 
and SDF-1, which attract blood monocytes and stimulate 
their migration into tumor tissues (Table 1). Th  ese  mono-
cytes ultimately fuse to form osteoclast-like, multinucle-
ated giant cells (Fig. 1). The monocytes express receptor 
activator of nuclear factor kappa (RANK) receptor and 
GCT stromal cells express RANKL which are essential 
for mature osteoclast diff  erentiation and activation with a 
cofactor macrophage colony-stimulating factor (M-CSF). 
Osteoclasts-like multinucleated giant cells are able to re-
sorb the bone, leading to osteolysis.
Recent advances in understanding key osteoclas-
togenic factors have shed light on the resorptive aspects 
of GCT.
15,16) Analysis of gene expression in GCT samples 
along with cytokine and chemokine studies are beginning 
Fig. 1. Osteoclastogenesis by giant-
cell tumor is constituted of stromal cells 
(GCTSCs). A diagram representing patho-
physiology of osteoclast-rich giant-cell 
tumor (GCT). A neoplastic component 
of GCT is mainly dysfunctional stromal 
cells. Mesenchymal stromal cell mark  ers 
such as STRO-1 and SDF-1α are posi  tive. 
Stromal cells produce sufficient chemo-
kines and cytokines which recruit CXCR4 
(+) osteoclast precursors from blood 
vessels and promote osteoclastogenesis. 
SDF: stromal cell-derived factor, MCP: 
monocyte chemoattractant protein, TNF: 
tumor necrosis factor, IL: interleukin, 
RANKL: receptor activator of nuclear 
factor kappa-B ligand, RANK: receptor 
activator of nuclear factor kappa, M-CSF: 
macrophage colony-stimulating factor.110
Kim et al. Modern Interpretation of Giant Cell Tumor of Bone
Clinics in Orthopedic Surgery • Vol. 4, No. 2, 2012 • www.ecios.org
to clarify some of the origins and actions of GCT compo-
nents. As extensively identified by histological analysis, 
the major cellular components of the GCT is constituted 
of stromal cells (GCTSC), mononuclear monocyte cells 
(MNMC), and multinucleated giant-cells (MNGC).
17) Th  e 
stromal cells are the main neoplastic component of GCTs 
and while they are not directly responsible for resorptive 
activity, they have been shown to express and secrete a 
variety of chemotactic factors to enlist pathologic compo-
nents.
2) MNMCs are considered to be either reactive mac-
rophages or osteoclast precursors. Th   e main reactive com-
ponents of GCTs are the multinucleated giant-cells which 
mimic osteoclasts. This is supported by the comparison 
between the cellular factors associated with osteoclasts to 
GCT samples. 
Osteoclasts develop from hematopoietic cells of the 
monocyte/macrophage lineage, whereas multinucleated 
giant cells are thought to be formed from blood mono-
cytes through tumor-induced cell fusion. The MNGC in 
GCT resemble many of the qualities of osteoclasts includ-
ing the expression of monocyte/macrophage markers like 
CD68, titrate-resistant acid phosphatase (TRAP), cathep-
sin K, matrix metalloproteinase (MMP)-9, and vitronectin 
receptors.
5)
CYTOKINES AND CHEMOKINES
The cellular environment of GCT is rich with cytokines 
and chemokines, i.e., cytokines with chemoattractive 
properties (Fig. 1). Due to recent studies of GCT-associ-
ated chemokines, the role that GCTSC initiate monocyte 
recruitment and giant-cell fusion is becoming clearer. 
mRNA analysis of GCTSCs illustrated the encoding of 
numerous osteoclastogenic cytokines and chemokines 
such as interleukin (IL)-6, IL-11, IL-17 as well as parathy-
roid hormone-related protein (PTHrP) and transforming 
growth factor-beta (TGF-β).
15) TGF- β1 is commonly pro-
duced by the bone and is known as a potent chemotactic 
agent for monocytes and macrophages. Furthermore, 
TGF-β type II receptor has been shown to be expressed 
in osteoclast-like GCT cells, thereby highlighting the role 
that stromal cells have in the fusion of multinucleated 
giant-cells.
18) TGF-β may also play a role in the expression 
of other cytokines found in GCT samples such as tumor 
necrosis factor (TNF)-α, interferon (IFN)-γ, and IL-1 
since TGF-β has been shown to upregulate these cytokines 
in other cells.
The recruitment of monocytes and osteoclast pre-
cursors by GCTSC is strengthened by the migration of 
CD14- monocytes, CD68+ macrophages, and CD34+ he-
matopoietic stem cells to GCT-conditioned media, which 
contains chemotactic concentrations of SDF-1.
9) Th  is  illus-
trates a strong involvement of GCTSC in the recruitment 
of osteoclast precursor cells for pathologic osteoclastogen-
esis.
19,20)
The discovery and subsequent exploration into 
the osteoclast differentiation factor (ODF)/RANKL/tu-
mor necrosis factor-related activation-induced cytokine 
(TRANCE) osteoclastogenic cytokine in GCT samples 
has led to considerable gains in the knowledge of fusion of 
monocytes. RANKL and M-CSF are widely known to be 
unequivocally required cytokines in normal osteoclasto-
genesis.
21,22) RANKL is a member of the TNF family, and 
is expressed by many cell types - including stromal cells.
23) 
Many studies confi  rmed RANKL to be highly expressed in 
GCTSC.
19,24-26) The monocytes recruited in GCTs express 
the RANK receptor and thus can take advantage of this 
neoplastic osteoclastogenic pathway. Studies performed by 
Atkins et al. revealed that neoplastic stromal cells of GCTs 
share phenotypic traits such as cytokine and gene expres-
sion to osteoblasts.
15,19,26) This suggests a neoplastic para-
digm of the physiological osteoblast-osteoclast structure 
involving GCT stromal cells and monocytes.
The expression of IL-1 by the osteoclastic cells of 
GCTs account for the increased activity of MMP-9, which 
is an osteoclast bone matrix resorptive enzyme. Further-
more, IL-1 is linked to the metastatic activity of GCT since 
it has been correlated with increased vascular and lung 
invasion.
2) The locally aggressive osteolytic activity that 
giant-cells exhibit is further explained by the expression of 
other matrix metalloproteinases such as type IV collage-
nase (MMP-2).
27-29)
IL-6 overexpression in GCT samples is yet another 
factor that is implicated in multi-nucleated giant cell for-
mation.
30) Due to this overexpression, c-Jun is activated 
in GCTSCs which leads to the inhibition of osteoblastic 
diff  erentiation of these stromal cells and enhanced onco-
genesis of GCT by acting as a proto-oncogene.
31) IL-6 is 
involved in the regulation of bone resorptive activity by 
giant-cells in GCTs and other giant-cell lesions. IL-6 neu-
tralizing antibodies have also been able to reduce resorp-
tion in a dose dependent manner.
30) Cell-cycle regulators 
such as IL-6 and similar proteins provide a channel to 
understanding pathogenic processes such as GCT with 
strong implications on therapeutic development.
Cytogenetic Findings
Along with cytokine and chemokine analysis, diff  erential 
gene expression in GCT samples can yield relevant in-
sights into the pathophysiology of this neoplasm, which 111
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can be used in the exploration of treatment options. Babe-
to et al.
32) used rapid subtractive hybridization (RaSH) to 
identify genes like kinectin, Rho-associated coil containing 
protein kinase 1, and sterile alpha motif and leucine zipper 
containing kinase (KTN1, ROCK1, and ZAK) which were 
diff  erentially expressed in GCT when compared to normal 
bone samples. KTN1, which encodes kinectin, a mem-
brane receptor involved in the transport of vesicles along 
microtubules, is highly expressed in GCT cells. ROCK1 is 
upregulated in GCT cells and encodes proteins associated 
with Rho kinase which are involved in cellular functions 
such as regulation of cell migration, gene expression and 
apoptosis as well as reorganization of the actin cytoskel-
eton. Thus ROCK1 upregulation could play a role in the 
metastatic potential of GCTs.
32) Alternatively, ZAK stops 
the cell cycle in the G2 phase. Th   e low expression of this 
gene leads to a halt in proliferation and support for a larger 
growth of giant-cell lesions in GCTs. 
Metastatic Potential
Although GCTs are classifi  ed as benign, with aggressively 
destructive local activity, they exhibit possible metastatic 
potential upon recurrence.
33-36) In up to 3% of the cases,
35) 
GCTs have been reported to metastasize to pulmonary tis-
sue.
33,35,37,38) Other possible yet exceedingly rare metastatic 
locations for GCT to arise is in the breast tissue.
39) Th  ese 
metastasized tumors present a challenge in treatment as 
they can arise in surgically unsuitable locations and have 
higher rates of recurrence. Based on a longitudinal review 
of cases, local recurrence in metastasized GCTs was found 
to be near 63%.
40) This suggests that the metastasized 
forms of the tumor might be more aggressive.
Modern experimentations such as proteomic 
screening can help us identify the metastatic potential and 
elucidate the mechanism of GCT pathology. Comparative 
proteomics analysis had led to the identification of bio-
markers possibly involved in recurrence and metastasis. 
Certain factors in primary tumors such as glutathione per-
oxidase 1 are strongly related to metastasis.
41) The use of 
cutting edge scientifi  c methods to uncover the pathophysi-
ological scheme of GCT will be essential in the discovery 
of new and more eff  ective treatment options.
TREATMENTS
Surgical Treatment
Prior to the advancement of new technology and develop-
ment of novel surgical techniques, GCT of the bone were 
treated by amputations of the body extremities.
3) This 
technique commonly left   the patient with emotional and 
physical distress due to functional limitations. Aft  er Volk-
man developed curettage, a technique of scooping out 
tissues, Mikulicz successfully used this technique to treat 
patients with GCTs without the need of amputations.
3) 
Furthermore, the development of newer technologies led 
to creation of surgical drills such as high speed burr, which 
facilitated the removal of tumors with higher effi   ciency.
42) 
In 1969, Marcove and Miller
43) introduced a new adjuvant 
technique of tumor removal known as cryosurgery where 
liquid nitrogen is utilized to freeze the tumor cells, which 
is subsequently thawed. Th   is process is repeated multiple 
times to cause the necrosis of pathogenic cells. Although 
cryosurgery has been shown to be a method of efficient 
tumor removal, the possibility of other complications has 
been noted, including the possibility of bone fracture and 
skin necrosis.
44) In some cases, the tumor may be too large 
to be removed by curettage. In these situations, wide resec-
tion, a more aggressive surgical treatment, may be neces-
sary to remove the tumor completely.
45)
In order to reconstruct bone defects aft  er the remov-
al of the tumor, bone grafting has been used.
3) Synthetic 
grafts such as polymethylmethacrylate (PMMA) have 
improved patient recovery and tumor removal due to the 
graft  ’s exothermic reaction that causes thermal necrosis of 
cells and innate infl  ammatory reaction.
45,46) Currently, all 
of these surgical techniques and graft  s are commonly used 
to treat GCTs,
47) yet the possibility of recurrence of the tu-
mor still remains an issue in not only within the bone, but 
also in the surrounding soft tissues.
48) To further reduce 
the rate of recurrence, many surgeons are combining sur-
gical treatment with other adjuvant therapies.
Recurrence
Th   e recurrence of GCTs remains a hot topic in the fi  eld of 
musculoskeletal tumors and the best treatment for these 
tumors remain controversial. Certain surgical procedures 
such as wide-excision and intralesional procedures along 
with the use of adjuvant therapies like PMMA, phenol, and 
local chemical application all aff  ect the rate of recurrence. 
In a study of 384 procedures, the highest rate of recurrence 
was observed to be from 35 to 49% in intralesional proce-
dures without the use of adjuvants.
49,50) However, there was 
a dramatic decrease in recurrence with PMMA, PMMA 
with phenol, and phenol with other chemical adjuvants 
at 22%, 27% and 15%, respectively.
49) Similar results were 
reported by Klenke et al.
50) in their retrospective study of 
46 patients. The use of PMMA with intralesional curet-
tage lowers the recurrence rate from the average of 32% to 
14%. Th   e recurrence rates seen for wide resection are near 
5-6%,
50,51) but they entail considerable loss of function. In 112
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another series, Klenke et al.
51) reported on the recurrence 
rates of GCT in 118 patients treated with wide resection 
and intralesional curettage and the rates are 5% and 25%, 
respectively. However, they suggested the use of curettage 
with PMMA, since this procedure lowers the recurrence 
rate and it provides equivalent tumor control compared 
to resection.
50,51) In a multicentric retrospective Canadian 
sarcoma study, 186 patients with GCT were followed for 
an average of 5 years.
52) Th   e authors found the recurrence 
rates of GCT are 18% after intralesional curettage with 
the combination of adjuvants and 16% aft  er resection. In 
contrast, Algawahmed et al.
53) suggested that surgical ad-
juvants are not required since the data from 387 patients 
did not show signifi  cant diff  erence in the recurrence rate 
compared to the control with the use of the toxic adjuvants 
in addition to high-speed burring.
Pathologic fracture through GCT is considered to be 
a risk factor of recurrence and poor functional outcome. 
Th   e 5-year recurrence free survival rates is reported 82.6% 
with fracture and 77.9% without fracture. However, the 
functional outcome is similar in both groups and arthrofi  -
brosis is more common in GCT group with fracture.
54)
Th   e tenacious nature of GCT recurrence has led to 
the rise of adjuvant therapies in surgical treatment. The 
use of bisphosphonates has been shown to yield lower 
recurrence rates in a dose dependent manner in vitro.
11) 
Innovations in adjuvant therapy gained from a better un-
derstanding of the molecular mechanisms of pathologic 
bone-resorption and neoplastic activity can be utilized to 
halt the incidence of recurrence of GCT.
Adjuvant Th   erapy (Table 2)
Chemical adjuvant therapy
To decrease the incidence of recurrence in patients, multi-
ple adjuvant therapies have been proposed and applied for 
the treatment of GCT. Application of chemical adjuvants 
such as alcohols, phenol, hydrogen peroxide, and zinc 
chloride to the aff  ected area has been shown to dramati-
cally reduce the rate of tumor recurrence in many cases.
7) 
Alcohols have been used for decades in surgeries for anti-
septic purposes, and it has been used as a safe adjuvant for 
the treatment of GCTs.
7,46,55) Ever since 1980, phenol has 
been used commonly as a local adjuvant for the GCT.
1,7) 
Although some studies have highlighted the efficacy of 
phenol as a local adjuvant for treating GCT,
7,56) others have 
revealed no signifi  cant diff  erence in the recurrence rate of 
phenol treated versus non-phenol treated patients. Th  ere-
fore, it was concluded that the success of tumor removal 
by surgery is a greater factor for determining the possibil-
ity of recurrence rather than the use of phenol.
57) Hydro-
gen peroxide has also been shown to affect GCT cells in 
vitro
1,58) and in patient studies.
59) Th   ough hydrogen perox-
ide has been recommended for GCT treatment due to its 
short-life,
7) this adjuvant has also been shown to increase 
Table 2. Adjuvant Therapies for GCT
Local chemical and physical adjuvants
Cryosurgery (liquid N) With the use of liquid nitrogen, the tumor is subjected to a freeze/thaw cycle in an attempt to cause cellular necrosis. 
Alcohols An organic compound used for antiseptic purposes. Anhydrous alcohols have been reported to be a safe adjuvant for the 
treatment of GCT.
Phenol A chemical which has antiseptic properties and removes microscopic tumor residuals
Hydrogen peroxide Oxidizing effervescent which is used to clean and removal tumor cell residues
Zinc chloride A chemical compound, which causes cell necrosis and is used to inhibit reoccurrence of GCT
Argon beam coagulation Cryotherapy that causes thermal necrosis of GCT and is used to lower the local recurrence
Mechanism-based drugs
Denosumab Human monoclonal antibody which targets RANKL, thereby inhibiting the formation and function of giant osteoclast-like 
cells of the tumor
Bisphosphonates A series of drugs that strongly attaches to hydroxyapatite of the bone and are then ingested by resorptive cells, leading to 
apoptosis of these cells. Bisphosphonates also have activity against cancerous cells. 
IFNα A protein produced by leukocytes and is involved in immune response. IFNα is an antiangiogenic inhibitor, which obstructs 
angiogenesis and tumor growth by targeting growth factors (e.g., bFGF, VEGF).
GCT: giant cell tumor, RANKL: receptor activator of nuclear factor kappa-B ligand, IFNα: interferon alpha, bFGF: basic ﬁ  broblast growth factor, VEGF: vascular 
endothelial growth factor. 113
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the penetration of phenol though the tissues, causing some 
chemical burns.
59) Thus, great care is needed when us-
ing these chemicals for GCT therapy. In addition to these 
chemicals, zinc chloride is another cytotoxic chemical 
which was supported for its use as an adjuvant for GCT 
treatment by Bloodgood
4) and have been used for treating 
patients with GCT.
44) In addition, Argon laser beam co-
agulation is an adjuvant treatment option for GCT which 
causes thermal necrosis and is associated with a low rate of 
local recurrence of GCT of bone.
60)
Radiation therapy
Radiation therapy for GCT was initially performed by 
Pfahler and Parry in 1932.
3) Although there are several 
reports of post-radial sarcoma development,
3,61,62) several 
studies have suggested radiation for the treatment of GCT 
when surgical treatments are not feasible.
63-66) Radiation 
seems to be less popular as a modern molecular therapy 
targeting osteoclastogenesis emerges.
Molecular adjuvant therapy
In addition to chemical adjuvants, drugs which have spe-
cific activity at the molecular level have been shown to 
have anti-GCT activities. These molecular drugs include 
Denosumab and bisphosphonates. Several studies have re-
vealed intricate similarities of GCT cells to the osteoclasts 
of bones.
24,47) For instance, RANKL, an essential molecule 
for osteoclast differentiation in bone metabolism, was 
found to be highly expressed in the cells of GCT.
15,24,67) Th  is 
observation hinted the possible involvement of RANKL 
in the pathogenesis of GCT and led to the idea of using 
RANKL-targeting drugs, such as Denosumab, to combat 
against this bone tumor.
68) Currently, Denosumab is in 
clinical trials for the treatment of GCTs.
68) Additionally, 
the similarities observed between the giant cells of the tu-
mor and osteoclasts of bone led scientists to test the eff  ect 
of bisphosphonates (anti-osteoclastic drugs) on GCTs. Th  e 
results verifi  ed the anti-GCT activities of bisphosphonates, 
such as pamidronate and zoledronate, in vitro
11,69,70) and in 
patient studies.
8,69,71) Th   ese studies show the possibility of 
using these target-specifi  c drugs for therapeutic purposes 
in treating GCTs near future.
Furthermore, studies of GCT revealed expressions of 
several angiogenic growth factors.
72) Th  is  fi  nding led to the 
proposal of using IFNα as an anti-angiogenic agent for the 
treatment of this debilitating disease. The application of 
IFNα for the treatment of GCT was initially conducted in 
1995 by Kaban et al.,
73) in which they successfully treated 
a 5-year-old girl who had the tumor in the jaw. Aft  er this 
successful treatment, several studies have also found IFNα 
to be an eff  ective treatment option for GCT patients.
74,75)
CONCLUSIONS
GCT or osteoclastoma has been a hot topic in the fi  eld of 
musculoskeletal tumors owing its predominant presence 
of osteoclast-like multinucleated giant cells. The name 
GCT or osteoclastoma gives a false impression of a tu-
mor comprising of proliferating osteoclasts or osteoclast 
precursors. The cytokine environment coupled with tu-
morigenic gene expression causes neoplastic GCT stromal 
cells to fail to diff  erentiate into osteoblasts. Subsequently, 
the stromal cells induce a chain of osteoclastogenesis by 
recruiting osteoclast precursors and supplying key pro-
osteoclastogenic cytokines. Current biological knowledge 
of osteoclastogenesis and cytokine expression of GCT 
leads to the contention that this neoplasm is a POST. In 
regards to treatments, several adjuvant therapies have been 
used for the treatment of GCT. However, the use of adju-
vant therapies alone in GCT treatment has been shown 
to be insuffi   cient for tumor riddance. With this in mind, 
the current option for eff  ective removal of the tumor and 
avoiding recurrence may be combinatory therapy, which 
includes vigorous tumor removal by surgery with other 
adjuvant therapies. Moreover, molecular drugs, which 
target cellular components involved in the pathology of 
GCT, may help decrease the rate of recurrence. Through 
a more modern approach focusing on pathophysiology, a 
wealth of mechanism-based treatments for GCT are sure 
to emerge.
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